EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis

Louis Boutin, Agnieszka Latosinska, Harald Mischak, Benjamin Deniau, Ayu Asakage, Matthieu Legrand, Etienne Gayat, Alexandre Mebazaa, Christos E Chadjichristos, François Depret iD

Intensive Care Medicine · 2023

DOI: 10.1007/s00134-023-07198-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Intensive Care Medicine, 2023. Verfasst von Louis Boutin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Critical Care Medicine and Burn Unit, FHU PROMICE AP-HP, Saint Louis and DMU Parabol, AP-HP, Université Paris Cité, 750…. Hauptthemen laut MEDLINE: Acute Kidney Injury, Peptides. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: PHRC - public grant, APHP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Acute kidney injury (AKI) is a frequent and severe condition in intensive care units (ICUs). In 2020, the Acute Dialysis Quality Initiative (ADQI) group proposed a new stage of AKI, referred to as stage 1S, which represents subclinical disease (sAKI) defined as a positive biomarker but no increase in serum creatinine (sCr). This study aimed to determine and compare the urinary peptide signature of sAKI as defined by biomarkers. METHODS: This is an ancillary analysis of the prospective, observational, multinational FROG-ICU cohort study. AKI was defined according to the Kidney Disease Improving Global Outcome definition (AKIKDIGO). sAKI was defined based on the levels of the following biomarkers, which exceeded the median value: neutrophil gelatinase-associated lipocalin (pNGAL, uNGAL), cystatin C (pCysC, uCysC), proenkephalin A 119-159 (pPENKID) and liver fatty acid binding protein (uLFABP). Urinary peptidomics analysis was performed using capillary electrophoresis-mass spectrometry. Samples were collected at the time of study inclusion. RESULTS: One thousand eight hundred eighty-five patients had all biomarkers measured at inclusion, which included 1154 patients without AKI (non-AKIKDIGO subgroup). The non-AKIKDIGO subgroup consisted of individuals at a median age of 60 years [48, 71], among whom 321 (27.8%) died. The urinary peptide signatures of sAKI, regardless of the biomarkers used for its definition, were similar to the urinary peptide signatures of AKIKDIGO (inflammation, haemolysis, and endothelial dysfunction). These signatures were also associated with 1-year mortality. CONCLUSION: Biomarker-defined sAKI is a common and severe condition observed in patients within intensive care units with a urinary peptide signature that is similar to that of AKI, along with a comparable prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Kidney InjuryPeptidesHumansMaleBiomarkersFemaleProspective StudiesMiddle AgedAgedPrognosisIntensive Care UnitsCystatin CLipocalin-2EnkephalinsCreatinineFatty Acid-Binding ProteinsProtein Precursors

Stichwörter der Autor:innen

Intensive care unitRenal biomarkersSubclinical AKIUrinary peptide signature

Substanzen

BiomarkersCystatin CPeptidesproenkephalinLipocalin-2EnkephalinsCreatinineFatty Acid-Binding ProteinsProtein Precursors

Autor:innen und Institutionen

  • Department of Anesthesiology, Critical Care Medicine and Burn Unit, FHU PROMICE AP-HP, Saint Louis and DMU Parabol, AP-HP, Université Paris Cité, 75010, Paris, France.
  • UMR-942, MASCOT, INSERM, Cardiovascular Markers in Stress Condition, Université de Paris, 75010, Paris, France.
  • UMR-S1155, Faculty of Medicine, INSERM Bâtiment Recherche, Tenon Hospital Sorbonne University, 75020, Paris, France.
  • Mosaiques Diagnostics GmbH, Hannover, Germany.
  • Department of Anesthesiology and Peri-Operative Medicine, Division of Critical Care Medicine, University of California, UCSF Medical Center, 500 Parnassus Ave, San Francisco, CA, 94143, USA.
  • Department of Anesthesiology, Critical Care Medicine and Burn Unit, FHU PROMICE AP-HP, Saint Louis and DMU Parabol, AP-HP, Université Paris Cité, 75010, Paris, France. francois.depret@aphp.fr.

ORCID-Profile: François Depret

Förderung

  • PHRC - public grant
  • APHP

Zitieren

APA

Boutin, L., Latosinska, A., Mischak, H., Deniau, B., Asakage, A., Legrand, M., Gayat, E., Mebazaa, A., Chadjichristos, C. E., & Depret, F. (2023). Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis. Intensive Care Medicine. https://doi.org/10.1007/s00134-023-07198-2

Vancouver

Boutin L, Latosinska A, Mischak H, Deniau B, Asakage A, Legrand M, et al. Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis. Intensive Care Medicine. 2023. doi:10.1007/s00134-023-07198-2

BibTeX
@article{Boutin2023,
  author = {Boutin, Louis and Latosinska, Agnieszka and Mischak, Harald and Deniau, Benjamin and Asakage, Ayu and Legrand, Matthieu and Gayat, Etienne and Mebazaa, Alexandre and Chadjichristos, Christos E and Depret, François},
  title = {Subclinical and clinical acute kidney injury share similar urinary peptide signatures and prognosis},
  journal = {Intensive Care Medicine},
  year = {2023},
  doi = {10.1007/s00134-023-07198-2}
}
Kostenlos starten →